Mier-Jedrzejowicz A K, Brophy C, Green M
Respiratory Muscle Laboratory, Brompton Hospital, London, United Kingdom.
Am Rev Respir Dis. 1988 Oct;138(4):867-73. doi: 10.1164/ajrccm/138.4.867.
Global respiratory muscle function and diaphragmatic strength were assessed and compared with quadriceps femoris muscle strength in 17 patients with generalized mild-to-moderate myasthenia gravis and breathlessness. Initial measurements, made 10 h after the last dose of oral anticholinesterase therapy, demonstrated reduced maximal static expiratory (52.4 +/- 26.8% predicted) and inspiratory (54.0 +/- 23.5% predicted) mouth pressures in 16 patients, and reduced quadriceps femoris muscle strength in all cases. Vital capacity (VC) (70.9 +/- 19.0% predicted) was abnormal in 12 patients. Transdiaphragmatic pressure recorded during maximal sniffs (sniff Pdl) was reduced in eight patients, whereas pressure recorded during bilateral phrenic nerve stimulation at 1 Hz (twitch Pdi) was reduced in only three. There was no relationship between the grade of myasthenia or the severity of dyspnea and any of the measurements of respiratory muscle strength. After the administration of edrophonium hydrochloride (Tensilon), there was a significant increase in maximal static expiratory and inspiratory mouth pressures in quadriceps muscle strength and in sniff Pdi. The small increase in VC was not significant, and twitch Pdi increased in only one patient. Phrenic nerve conduction time was normal before and after Tensilon. Two patients with severe long-standing myasthenia showed no improvement in any measurement after Tensilon. We conclude that expiratory and inspiratory muscle weakness was not uncommon in patients with myasthenia gravis. Respiratory muscle strength improved after Tensilon. Vital capacity was a less sensitive measure of respiratory muscle strength than were respiratory mouth pressures and sniff Pdi. Diaphragmatic involvement was not detected by twitch Pdi unless the weakness was severe.(ABSTRACT TRUNCATED AT 250 WORDS)
对17例患有全身性轻至中度重症肌无力且伴有呼吸急促的患者,评估其全球呼吸肌功能和膈肌力量,并与股四头肌力量进行比较。在最后一剂口服抗胆碱酯酶治疗10小时后进行的初始测量显示,16例患者的最大静态呼气(预测值的52.4±26.8%)和吸气(预测值的54.0±23.5%)口腔压力降低,所有病例的股四头肌力量均降低。12例患者的肺活量(VC)(预测值的70.9±19.0%)异常。8例患者在最大吸气时记录的跨膈压(吸气Pdl)降低,而在双侧膈神经以1Hz刺激时记录的压力(抽搐Pdi)仅3例降低。重症肌无力的分级或呼吸困难的严重程度与呼吸肌力量的任何测量值之间均无关联。给予盐酸依酚氯铵(腾喜龙)后,最大静态呼气和吸气口腔压力、股四头肌力量及吸气Pdi均显著增加。VC的小幅增加不显著,仅1例患者的抽搐Pdi增加。腾喜龙前后膈神经传导时间正常。2例患有严重长期重症肌无力的患者在腾喜龙治疗后任何测量值均无改善。我们得出结论,重症肌无力患者中呼气和吸气肌无力并不罕见。腾喜龙治疗后呼吸肌力量有所改善。与呼吸口腔压力和吸气Pdi相比,肺活量是呼吸肌力量较不敏感的测量指标。除非肌无力严重,抽搐Pdi无法检测到膈肌受累。(摘要截短于250字)